Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer

Author:

de la Brassinne Bonardeaux Orianne1,Born Benjamin2,Moonen Marie1,Lancellotti Patrizio1

Affiliation:

1. Department of Cardiology, GIGA Cardiovascular, University of Liège Hospital, 4000 Liège, Belgium

2. Intensive Care Department, Citadelle of Liège Hospital, 4000 Liège, Belgium

Abstract

Breast cancer is the leading cause of cancer death in women worldwide. Trastuzumab, the main HER2-targeted treatment, faces limitations due to potential cardiotoxicity. The management of patients with mild cardiotoxicity on trastuzumab remains uncertain, resulting in treatment discontinuation and negative oncological outcomes. This retrospective study analyzed 23 patients who experienced decreased left ventricular function during trastuzumab treatment. During the 18-month follow-up period, two patients (9%) had severe declines in function, leading to treatment cessation, and one patient (4%) developed heart failure symptoms. However, 21 patients showed mild, reversible myocardial dysfunction without significant differences in final ventricular function compared to a control group (58.4% vs. 61.7%, respectively; p = 0.059). The declines in function were most pronounced at nine months but improved at twelve and eighteen months. Various echocardiographic parameters changed significantly over time. As predictors of severe cardiotoxicity, we identified the following: LVEF before initial chemotherapy (p = 0.022), as well as baseline LVEF before treatment with trastuzumab (p = 0.007); initial left ventricular end systolic volume (p = 0.027); and the initial global longitudinal strain (p = 0.021) and initial velocity time integral in the left ventricular outflow track (p = 0.027). In conclusion, the continuation of trastuzumab should be considered for most patients with mild cardiotoxicity, with close cardiac monitoring and cardioprotective measures. However, identifying the patients at risk of developing severe cardiotoxicity is necessary. According to our data, the initial LVEF and GLS levels appear to be reliable predictors.

Publisher

MDPI AG

Subject

General Medicine

Reference39 articles.

1. World Health Organization International Agency for Research on Cancer (2020, August 17). The Global Cancer Observatory. 2018 Statistics. Available online: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.

2. Global cancer statistics, 2012;Torre;CA Cancer J. Clin.,2015

3. Breast cancer in Belgium: Why are we the first in Europe?;Desreux;Rev. Med. Liege,2011

4. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy;Heijnsdijk;Int. J. Cancer,2015

5. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality;Munoz;J. Natl. Cancer Inst.,2014

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3